Show simple item record

dc.contributor.authorCoutts, ASen
dc.contributor.authorPires, IMen
dc.contributor.authorWeston, Len
dc.contributor.authorBuffa, FMen
dc.contributor.authorMilani, Men
dc.contributor.authorLi, J-Len
dc.contributor.authorHarris, ALen
dc.contributor.authorHammond, EMen
dc.contributor.authorLa Thangue, NBen
dc.date.accessioned2017-11-27T20:03:40Z
dc.date.available2017-11-27T20:03:40Z
dc.date.issued2011-12-01en
dc.identifier.urihttp://hdl.handle.net/10026.1/10339
dc.description.abstract

Junction-mediating and regulatory protein (JMY) is a novel p53 cofactor that regulates p53 activity during stress. JMY interacts with p300/CBP, which are ubiquitous transcriptional co-activators that interact with a variety of sequence-specific transcription factors, including hypoxia-inducible factor-1α (HIF-1α). In addition, JMY is an actin-nucleating protein, which, through its WH2 domains, stimulates cell motility. In this study, we show that JMY is upregulated during hypoxia in a HIF-1α-dependent manner. The JMY gene contains HIF-responsive elements in its promoter region and HIF-1α is recruited to its promoter during hypoxia. HIF-1α drives transcription of JMY, which accounts for its induction under hypoxia. Moreover, the enhanced cell motility and invasion that occurs during hypoxia requires JMY, as depleting JMY under hypoxic conditions causes decreased cell motility. Our results establish the interplay between JMY and HIF-1α as a new mechanism that controls cell motility under hypoxic stress.

en
dc.format.extent4835 - 4842en
dc.languageengen
dc.language.isoengen
dc.subjectBase Sequenceen
dc.subjectCell Hypoxiaen
dc.subjectHumansen
dc.subjectHypoxia-Inducible Factor 1, alpha Subuniten
dc.subjectMolecular Sequence Dataen
dc.subjectNuclear Proteinsen
dc.subjectPromoter Regions, Geneticen
dc.subjectTrans-Activatorsen
dc.titleHypoxia-driven cell motility reflects the interplay between JMY and HIF-1α.en
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/21625218en
plymouth.issue48en
plymouth.volume30en
plymouth.publication-statusPublisheden
plymouth.journalOncogeneen
dc.identifier.doi10.1038/onc.2011.188en
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine
dc.publisher.placeEnglanden
dc.identifier.eissn1476-5594en
dc.rights.embargoperiodNot knownen
rioxxterms.versionofrecord10.1038/onc.2011.188en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.typeJournal Article/Reviewen


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV